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1pharmazentrum frankfurt/ZAFES, University Hospital Goethe-University Frankfurt, 2Clinic for Anesthesiology, University Hospital
Ludwig-Maximilians-University Munich, 3Medical Clinic I, University Hospital Goethe-University Frankfurt, Germany.
Overdosing of the analgesic acetaminophen (APAP, paracetamol) is a major cause of acute liver injury.
Whereas toxicity is initiated by hepatocyte necrosis, course of disease is regulated by mechanisms of innate
immunity having the potential to serve in complex manner pathogenic or pro-regenerative functions.
Interleukin (IL)-36c has been identified as novel IL-1-like cytokine produced by and targeting epithelial
(-like) tissues. Herein, we investigated IL-36c in acute liver disease focusing on murine APAP-induced
hepatotoxicity. Enhanced expression of hepatic IL-36c and its prime downstream chemokine target CCL20
was detected upon liver injury. CCL20 expression coincided with the later regeneration phase of
intoxication. Primary murine hepatocytes and human Huh7 hepatocellular carcinoma cells indeed
displayed enhanced IL-36c expression when exposed to inflammatory cytokines. Administration of IL-36
receptor antagonist (IL-36Ra) decreased hepatic CCL20 in APAP-treated mice. Unexpectedly, IL-36Ra
likewise increased late phase hepatic injury as detected by augmented serum alanine aminotransferase
activity and histological necrosis which suggests disturbed tissue recovery upon IL-36 blockage. Finally, we
demonstrate induction of IL-36c in inflamed livers of endotoxemic mice. Observations presented introduce
IL-36c as novel parameter in acute liver injury which may contribute to the decision between unleashed
tissue damage and initiation of liver regeneration during late APAP toxicity.
T
issue injury associated with inappropriate application of the analgesic acetaminophen (APAP, paracetamol)
is a leading cause of acute liver failure and thus considered a major burden for health care systems world-
wide1. From a conceptual point of view, experimental APAP-induced liver injury is a valid model for
studying acute diseases initiated by parenchymal cell death, but likewise regulated by innate immunoactivation
in response to release of alarmins from necrotic or necroptotic cells2–4. Alarmins that supposedly contribute to
APAP-induced liver injury include DNA5,6 and ATP7 as well as protein factors such as high-mobility group box
protein-1 (HMGB1)8,9, and histones10. With the exception of ATP activating P2X7 receptors7, aforementioned
alarmins may aggravate disease by action on toll-like receptors (TLRs)2,3,11. Independent reports relate severity of
APAP-induced liver injury to activation of the innate TLR system mediating detrimental inflammation. This
specifically applies to TLR410,12,13, TLR314, and TLR95,9. However, the role of the innate immune system and
related cytokine production in APAP-induced liver damage is more complex and definitely includes the potential
to initiate protective mechanisms that associate with repair and regeneration15. Indeed, if tissue damage stays
below a threshold, resolution prevails and prevents loss of organ function by initiating compensatory prolifera-
tion, repair, and regeneration. Of note, crucial protective/pro-regenerative functions of liver macrophage/dend-
ritic cell/Kupffer cell populations are evident in the context of murine APAP intoxication16,17. This complexity is
also reflected by partly disparate results obtained in different studies evaluating fine-tuning of APAP toxicity. For
example, while confirming previous data on the pathogenic action of HMGB18 and TLR95, a recent report did not
support a role for TLR4 in mediating APAP-induced tissue damage9.
Some members of the interleukin (IL)-1 cytokine family18, for example IL-1a and IL-1b, are supposed to be
upregulated by alarmins during APAP-induced liver injury. However, the role of IL-1 in APAP toxicity is actually
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observed in APAP-induced liver injury. A further cytokine of the IL-
1 family able to efficiently activate epithelial (-like) cells is IL-36c22.
This cytokine, formerly known as IL-1F923, shows characteristic
properties shared by several IL-1 family members such as absence
of a conventional signal peptide18, the necessity for proteolytic mat-
uration to acquire full biological activity24, and usage of the IL-1
receptor accessory protein (IL-1RAcP) as one component of its het-
erodimeric receptor18,25. The other receptor component, IL-1 recep-
tor related protein-2 (IL-1Rrp2), specifically binds to IL-36c and its
siblings IL-36a or IL-36b and initiates, in cooperation with IL-
1RAcP, signaling via nuclear factor (NF)-kB and mitogen-activated
protein kinases25. Besides mononuclear phagocytes and T cells26,27,
especially cells of epithelial origin are sources and targets of IL-
36c22,28,29. Accordingly, IL-36c has been linked to the pathogenesis
of psoriasis22. Biological activity of IL-36 cytokines is controlled by
IL-36 receptor antagonist (IL-36Ra) which tightly binds IL-1Rrp2
but lacks the potential to recruit IL-1RAcP. Excess of IL-36Ra thus
blocks IL-36 function in a manner similar to the action of IL-1Ra on
IL-1 biological activity24. Furthermore, IL-38 is capable of inhibiting
IL-36c by analogous action30. The relevance of IL-36 in patho-
physiology is underscored by aggravated experimental psoriasis
upon IL-36Ra deficiency31,32. Even more impressive is the association
between non-functional IL-36Ra and the development of clinical
generalized pustular psoriasis, a most severe entity of dermal
inflammation33.
Since specific information on that matter is currently lacking, we
set out to investigate the significance of IL-36 cytokines in the hepatic
compartment with focus on APAP-induced liver injury.
Results
Expression of IL-36c in murine APAP-induced liver injury and
inflamed hepatocytes. Since IL-36c is a novel parameter potentially
determining the biology of ‘epithelial-like’ hepatocytes and thus
APAP-induced liver injury, we set out to investigate its expression
in this setting. As shown in Fig. 1A, upregulation of hepatic IL-36c
expression was detectable at 24 h, but not at 6 h, after application of
APAP. Notably, amelioration of APAP-induced liver disease by
administration of recombinant IL-2234,35 associated with modulation
of hepatic IL-36c (Fig. 1a), suggesting that expression of IL-36c may
link to disease severity. To assess the specificity of IL-36 expression in
APAP-induced liver injury, hepatic IL-36a and IL-36b were likewise
determined. Notably, IL-36c was by far the most abundantly
expressed IL-36 cytokine in this model of acute liver damage
(Fig. 1b). We previously reported on IL-36c expression in primary
human monocyte-derived dendritic cells or M1 macrophages under
the influence of IL-1b/TNFa/IFNc26. Yet, a characteristic feature of
IL-36c biology is its expression in activated cells of epithelial origin
such as keratinocytes28 and lung epithelial cells29. Therefore,
expression of IL-36c was investigated in primary murine
hepatocytes and human Huh7 hepatocellular carcinoma cells. Here,
we demonstrate upregulation of IL-36c by inflammatory IL-1b/
TNFa/IFNc in both cell types (Fig. 1cd). Notably, expression of IL-
15,20 as well as TNFa14,34,36–38 and IFNc37–39 has been detected in liver
tissue undergoing APAP-induced injury. Data presented thus suggest
hepatocytes, besides mononuclear phagocytes, as possible source of
IL-36c during inflammatory liver damage. To further investigate the
relevance of IL-36c for liver pathology, expression of IL-1Rrp2, the
decisive IL-36 receptor chain, was analyzed. Liver tissue IL-1Rrp2
mRNA was significantly upregulated 6 h after treatment of mice
with APAP (264 6 45% versus control mice (ctrl, see methods
section) set as 100%, means 6 SEM; n 5 6, p 5 0.0075, Student’s
t-test). At the 24 h time point after APAP administration, hepatic IL-
1Rrp2 mRNA levels had decreased to levels not significantly different
from those of ctrl mice (data not shown). Subsequent
immunohistochemical analysis revealed that augmented IL-1Rrp2
mRNA levels detectable in the early phase of intoxication
associated with enhanced protein expression at the 24 h time point
after APAP administration. IL-1Rrp2 protein was barely detectable
in healthy murine liver. Notably, IL-1Rrp2 protein was located at
the edges of centrilobular necrosis, a typical hallmark of APAP
intoxication (Fig. 1e). Altogether, data indicate IL-36 responsiveness
of the inflamed murine liver.
Expression of CCL20 in APAP-induced liver injury. The C-C
chemokine CCL20, also coined liver and activation regulated
chemokine, is among genes efficiently upregulated by IL-36c in
human primary keratinocytes26,28,40 and bronchial epithelial cells29.
Herein, we extend those observations to human, IL-1Rrp2 expressing
(data not shown), Huh7 hepatocellular carcinoma cells (4.0-fold
induction of CCL20 mRNA, 4 h incubation with IL-36c at 100 ng/
ml, n 5 3, p 5 0.0348, Student’s t-test) and human monocyte-
derived macrophages (463-fold induction of CCL20 mRNA, 4 h
incubation with IL-36c at 100 ng/ml, n 5 5, p 5 0.0012, Student’s
t-test), respectively.
Since CCL20 has been related to hepatic necroinflammation41, we
set out to investigate this chemokine in the context of APAP-induced
liver injury. Compared to IL-36c, CCL20 expression was induced
with a delayed kinetic showing up well after 24 h of exposure to
APAP (Fig. 2a). Amelioration of disease by application of IL-22
was, in similarity to observations on IL-36c, associated with signifi-
cant reduction of hepatic CCL20 expression (Fig. 2b).
Application of IL-36Ra decreases CCL20 expression but increases
parameters of tissue damage in late murine APAP-induced liver
injury. To assess the function of IL-36c in liver pathology, mice were
co-treated with recombinant murine IL-36Ra along with APAP
administration. After 48 h, hepatic chemokine expression and liver
damage as detected by histology and serum alanine aminotransferase
(ALT) activity was evaluated. In accord with data demonstrating
induction of CCL20 by recombinant IL-36c in cell culture,
significant reduction of hepatic CCL20 expression became evident
in mice that underwent APAP toxicity upon treatment with IL-36Ra.
Reduction of CCL20 by IL-36Ra was detected on mRNA (Fig. 3a)
and protein level (Fig. 3b), respectively. Notably, this was not the
result of a general anti-inflammatory effect of IL-36Ra, because
hepatic expression of CCL2 and CXCL2, both markers of local
hepatic inflammation, was either augmented or unaffected upon
IL-36Ra (Fig. 3c).
To determine the functional relevance of IL-36c blockage during
APAP-induced liver injury, serum ALT was analyzed. While not
significantly affecting serum ALT near the peak of hepatic injury at
24 h after APAP administration [8683 6 1123 units/liter (n 5 10)
versus 10221 6 1744 (n 5 9) for APAP versus APAP/IL-36Ra,
respectively], IL-36Ra application significantly upregulated this
parameter of liver injury in the late phase of intoxication at the
48 h time point (Fig. 4a). Accordingly, computer-based analysis of
histological liver sections demonstrated a significant 2-fold increase
of APAP-induced necrosis upon IL-36Ra treatment (Fig. 4b). Fig. 4c
displays representative 48 h time point liver sections derived from
mice undergoing either APAP (left panel) or APAP/IL-36Ra treat-
ment (right panel). Compensatory proliferation in late APAP tox-
icity was assessed by immunohistochemical analysis of Ki67, an
established marker of hepatocyte proliferation. As compared to mice
obtaining APAP alone, administration of IL-36Ra to APAP treated-
mice was associated with a significant 21.5 6 3.8% decrease of Ki67-
positive hepatocytes (n 5 8 for both groups, p 5 0.0155, Students
t-test) indicating some reduction of compensatory proliferation
under the influence of IL-36Ra.
IL-36c expression in livers of endotoxemic mice. To extend current
information on hepatic IL-36c expression to inflammatory
conditions different from APAP-induced liver injury, murine
endotoxemia was analyzed. As shown in table 1, endotoxemia
www.nature.com/scientificreports
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mediated, along with upregulation of prototypic markers of
inflammation such as TNFa, IL-1b, and IL-6, strong induction of
hepatic IL-36c and CCL20 mRNA expression.
Discussion
Analysis of hierarchically organized cytokine networks is key to
advance our understanding of diseases that associate with inflam-
matory processes. Here, we propose IL-36c as novel player in late
APAP-induced liver damage. Using murine endotoxemia, we con-
firm expression of IL-36c by the diseased liver.
Expression of IL-36c in murine liver was detectable at 24 h after
APAP administration, proposing that this cytokine regulates a later
phase of intoxication, which may coincide with tissue repair and
regeneration. At that time point, IL-1Rrp2, the IL-36 receptor, was
increased at the edges of centrilobular necrosis localizing IL-36c
action specifically to the site of extensive hepatic injury.
Amelioration of APAP-induced toxicity by administration of IL-22
reduced hepatic IL-36c expression. Altogether, these observations
suggest that release of alarmins from necrotic liver parenchyma in
the amplification/injury phase of intoxication15 mediates somewhat
delayed expression of IL-36c, possibly secondary to more proximal
inflammatory cytokines. In fact, induction of IL-36c was detected in
cultured murine primary hepatocytes or human Huh7 hepatocellular
carcinoma cells exposed to inflammatory IL-1/TNFa/IFNc. Beyond
parenchymal cells such as hepatocytes, we recently reported on IL-
36c expression by activated mononuclear phagocytes26. It should be
noted that the role of Kupffer cells and other macrophage lineages in
APAP toxicity is not discussed uniformly. Whereas mononuclear
phagocytes may contribute to early liver injury during initial intox-
ication42, those cells evidently initiate and promote the regeneration
phase of intoxication15.
On a functional level, we demonstrate that application of recom-
binant IL-36Ra significantly aggravates late phase liver damage, as
detected by histological analysis of liver necrosis and serum ALT
Figure 1 | Expression of IL-36c in murine APAP-induced liver injury and inflamed hepatocytes. (ab) Mice received PBS (n 5 6) or APAP or (where
indicated) APAP/IL-22 (6 h (n 5 6), 24 h (n 5 9)). (a) Hepatic IL-36c mRNA was determined by realtime PCR. Target mRNA was normalized to that of
GAPDH (means 6 SEM versus ctrl; **p , 0.01, ***p , 0.001 versus ctrl; #p , 0.05). (b) Hepatic IL-36abc mRNAs were determined by realtime
PCR. Target mRNA was normalized to that of GAPDH and is shown as raw data (22ddCt 3 107; means 6 SEM; ***p , 0.001 versus ctrl of the same target
gene; n.s., not significant). (ab) Statistical analysis, one-way analysis of variance with post hoc Bonferroni correction. (c) Murine primary hepatocytes
were kept as unstimulated control (ctrl) or stimulated with IL-1b/TNFa/IFNc (each 50 ng/ml). IL-36c mRNA expression was determined by realtime
PCR. Target mRNA was normalized to that of GAPDH (means 6 SEM versus ctrl; n 5 3). (d) Huh7 cells were kept as unstimulated ctrl or stimulated with
IL-1b/TNFa/IFNc (each 50 ng/ml). After 3 h (left panel) or 24 h (right panel), IL-36c mRNA (left panel) or protein (right panel) was determined by
realtime PCR or immunoblotting, respectively. Target mRNA was normalized to that of GAPDH (means 6 SD versus ctrl; n 5 8). One representative
immunoblot of five independently performed experiments is shown. (cd) Statistical analysis, Student’s t-test versus ctrl at the respective time point. (e)
Representative murine liver immunohistochemistry of IL-1Rrp2 at 24 h after APAP application (left panel: ctrl; right panel: APAP).
www.nature.com/scientificreports
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activity. Moreover, we observed that IL-36c determines induction of
CCL20 in this advanced phase of liver injury. This conclusion is
based on impaired CCL20 mRNA and protein expression after IL-
36Ra administration. IL-36Ra is a genuine receptor antagonist that
blocks activity of IL-36 by binding to IL-1Rrp224. However, activa-
tion of the orphan receptor SIGIRR was recently put forward as
additional mode of IL-36Ra action. SIGIRR curbs signaling by TLR
ligands or IL-1 cytokines thus inhibiting key inflammatory pathways,
among others NF-kB- and c-jun terminal kinase (JNK)-dependent
signalling43. A connection between SIGIRR and IL-36Ra was pro-
posed in light of early data indicating that upregulation of anti-
inflammatory IL-4 by IL-36Ra in the brain is abrogated in SIGIRR
knockout mice44. However, biochemical evidence supporting direct
binding of IL-36Ra to SIGIRR has not been presented. Several points
yet argue against SIGIRR as regulatory mechanism in the context of
data presented herein. First, activation of anti-inflammatory SIGIRR
would likely ameliorate APAP-induced liver injury. This assumption
also connects to the pathogenic role of JNK in APAP intoxication45
and the capability of IL-4 to ameliorate disease in this setting46. In
fact, we actually observed significantly augmented late histological
necrosis and serum ALT activity, a systemic parameter reflecting
liver damage, in IL-36Ra treated mice. Accordingly, IL-36Ra admin-
istration likewise associated with enhanced hepatic expression of
CCL2, a notorious surrogate of necroinflammation. Altogether, data
indicate that specific downregulation of CCL20 by IL-36Ra is
unlikely related to SIGIRR but mediated by blockage of IL-36c on
the level of IL-1Rrp2. In accord with the requirement of IL-36c
biological activity for efficient CCL20 induction in vivo, we observed
upregulation of this chemokine by IL-36c in cultured Huh7 hepato-
cellular carcinoma cells and primary macrophages.
Regulation of CCL20 by IL-36c may impact on the course of
APAP-induced disease. CCL20 is a C-C chemokine targeting
CCR6 as sole receptor. The complex biology of CCL20 is largely
based on functional CCR6 expression on T cell subsets with partly
opposing functions in pathophysiology, namely regulatory T cells
(Tregs), Th17 cells47, and cd T cells48. cdT cells have been
described to aggravate APAP-induced liver injury by producing
IL-178. A similar mode of pathogenic action supposedly applies to
Th17 cells that likewise accumulate in the liver upon APAP intox-
ication49. However, the liver-homing capacity of CCL20 may also
mediate tissue protection, repair, and regeneration. Notably, a
recent report demonstrates that the aforementioned CCL20-cdT
cell-IL-17-IL-22-axis likewise promotes liver regeneration after
experimental murine hepatectomy50. These observations suggest
that, in addition to differences in disease models, timing of cdT
cells action may be pivotal for their function on the course of liver
injury. Although the function of Tregs has, to the best of our
knowledge, not been reported so far for APAP intoxication, their
protective potential in acute liver injury is evident51. In fact, IL-10,
a major Treg product, is protective in APAP-induced liver
damage52. CCL20 may also directly stimulate hepatic stellate cells
(HSC), for example by activating pro-proliferative mitogen-acti-
vated protein kinases53. Notably, depletion of HSC worsens
experimental APAP intoxication54. The relevance of CCL20 acting
on HSC for repair in APAP-induced liver injury has not been
Figure 2 | CCL20 expression in murine APAP-induced liver injury. (a)
Mice received PBS (n 5 6) or APAP (6 h, n 5 6; 24 h, n 5 9; 48 h, n 5 11)
for indicated time points. Hepatic CCL20 and IL-36c mRNA was
determined by realtime PCR. Target mRNA was normalized to that of
GAPDH (means 6 SEM versus ctrl of target mRNA, ***p , 0.001 and ##p
, 0.01 versus ctrl at the respective time point). (b) Mice received PBS (n 5
6) or APAP (24 h (n 5 9) or 48 h (n 5 6)) or APAP/IL-22 (24 h (n 5 9) or
48 h (n 5 6)). Hepatic CCL20 mRNA was determined by realtime PCR.
Target mRNA was normalized to that of GAPDH (means 6 SEM versus
ctrl; ***p , 0.001 versus ctrl, ###p , 0.001). (ab) Statistical analysis, one-
way analysis of variance with post hoc Bonferroni correction).
Figure 3 | Application of IL-36Ra modulates CCL20 expression in late
murine APAP-induced liver injury. (abc) Mice received APAP (n 5 11) or
APAP/IL-36Ra (n 5 12) and were maintained for 48 h. Thereafter, hepatic
CCL20 mRNA (a) and protein (b) was determined by realtime PCR and
ELISA, respectively. (a) Target mRNA was normalized to that of GAPDH
and is shown as percent of APAP alone (means 6 SEM). (b) Liver tissue
CCL20 content was determined by ELISA, is depicted as pg/500 mg total
protein, and shown as means 6 SEM. (c) Hepatic CCL2 and CXCL2
mRNA was determined by realtime PCR. Target mRNA was normalized to
that of GAPDH and is shown as percent of APAP alone set as 100% (means
6 SEM). Statistical analysis, Student’s t-test; n.s., not significant.
www.nature.com/scientificreports
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investigated. However, as HSC are crucial for liver regeneration55,
their activation by CCL20 might be of significance.
Finally, aggravation of APAP-induced liver damage by IL-36Ra is
reminiscent of data on amelioration of toxicity detected in IL-1Ra
deficient mice21. In fact, it has been shown that IL-1 produced by
necrotic liver tissue is able to support regeneration by compensatory
hepatocyte proliferation via activation of the IL-6/STAT3 axis56. IL-
6, along with IL-22, is key to STAT3 activation in diseased liver
tissue57. Notably, IL-36c has been shown to efficiently induce IL-6
in mononuclear phagocytes27,40 and endogenous IL-6 displays pro-
tective/pro-regenerative action in APAP-induced liver injury58,59.
Herein, application of IL-36Ra reduced hepatocyte Ki67 expression
in the late regeneration phase of APAP-induced liver injury by 21%.
Albeit this effect appears modest, it indicates that impaired compens-
atory proliferation may contribute to aggravation of toxicity upon
IL-36 blockage. Observations suggest that, when biologically active,
IL-36c likely contributes to a mediator milieu favoring tissue repair/
regeneration in the later phase of APAP intoxication.
Altogether, the unexpected observation that blockage of IL-36c by
IL-36Ra exacerbates APAP-induced liver injury may reflect the
counterintuitive but inherent potential of some inflammatory cyto-
kines to initiate regeneration when adequately expressed at the right
time and place.
Methods
Reagents. APAP and lipopolysaccharide (LPS; O55:B5) were from Sigma-Aldrich,
Taufkirchen, Germany. Murine IL-22 was from Immunotools, Friesoythe, Germany.
Mature human IL-36c (aa18-aa169) and murine IL-36Ra were from R&D Systems,
Wiesbaden, Germany. IL-1b (human), TNFa (human, mouse), IFNc (human,
mouse), and human macrophage colony-stimulating factor (M-CSF) were from
Peprotech Inc., Frankfurt, Germany.
Murine APAP-induced liver damage and experimental endotoxemia. Experiments
using male C57Bl/6N mice (Charles River Laboratories, Sulzfeld, Germany; 8–10
weeks old) were approved by the Regierungspräsidium Darmstadt and were in
accordance with NIH guidelines. Before being sacrificed, mice underwent short
isoflurane (Abbott, Wiesbaden, Germany) anesthesia. Blood was drawn from the
retro orbital venous plexus. Serum ALT activity was quantified according to
manufacturer’s instructions (Reflotron, Roche Diagnostics, Mannheim, Germany).
For RNA analysis, liver tissue was snap frozen in liquid nitrogen and stored at 280uC.
For histological analysis, liver tissue was perfused with PBS via the portal vein
followed by overnight incubation in 4.5% buffered formalin. Paraffin-embedded liver
sections (4 mm) were stained with H&E. Histopathologic liver injury was quantified
in blinded manner by ImageJ 1.46r (NIH, Bethesda, MD) software. Murine APAP-
induced liver damage was induced as previously described34. Briefly, fasted male mice
obtained (as indicated) i.v. injections of PBS or IL-22 (3.5 mg/mouse) or IL-36Ra
(6 mg/mouse). Immediately thereafter, i.p. injection of either warm NaCl (0.9%,
B.Braun, Melsungen, Germany) or APAP (500 mg/kg dissolved in warm 0.9% NaCl)
was performed. Mice that obtained PBS followed by NaCl are depicted as control mice
(ctrl) throughout the manuscript. Mice had free access to food and water thereafter.
After indicated time points, mice were sacrificed. We experienced a relatively low
48 h-mortality rate in this model of murine APAP (500 mg/kg)-induced liver injury
(2/24 for APAP and 1/17 for APAP/IL-36Ra, respectively) which, however, agrees
with a recent report using a very similar experimental protocol17. Notably, at the
higher 750 mg/kg APAP dosage we observed an approximately 50% mortality rate
within a 24 h observation period (4/9)34.
For induction of endotoxemia, unfasted male mice were injected intraperitoneally
with either PBS or LPS (5 mg/kg dissolved in PBS). After three hours, mice were
sacrificed and hepatic cytokine expression was analyzed.
Immunohistochemical detection of IL-1Rrp2 and Ki67 in liver tissue. For
detection of hepatic IL-1Rrp2- and Ki67 positive cells, paraffin-embedded liver
sections (4 mm) were used. Sections were deparaffinized and unmasked by heat
treatment (Dako Target Retrieval Solution, Glostrup, Denmark). Thereafter, sections
were incubated with goat anti-murine IL-1Rrp2 antibody (R&D Systems, Wiesbaden,
Germany) or rabbit anti-murine Ki67 antibody (Epitomics, Burlingame, CA)
overnight at 4uC. For detection, rabbit anti-goat universal immuno-peroxidase
polymer (IL-1Rrp2) or goat anti-rabbit universal immune-peroxidase polymer (Ki-
67; both Nichirei Biosciences, Tokyo, Japan) and DAB Substrate Kit for Peroxidase
(Vector Laboratories, Burlingame, CA, USA) were used. Sections were
counterstained using hematoxylin.
Isolation of murine hepatocytes. For isolation of murine hepatocytes C57Bl/6N
mice were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.).
After disinfection and laparotomy, a 22 G cannula was placed in the inferior vena
cava. After dissection of the portal vein, retrograde liver perfusion was performed
with 37uC warm HBSS without Ca21 and Mg21 (supplemented with 15 mM HEPES,
2.5 mM EGTA, 1 g/l glucose, 100 U/ml penicillin, and 100 mg/ml streptomycin)
using a roller pump (10 ml/min) for 10 min. Next, the liver was perfused with HBSS
with Ca21 und Mg21 (supplemented with 15 mM HEPES, 5 mM CaCl2, 0.13 mg/ml
collagenase IV (Sigma-Aldrich), 100 U/ml penicillin, and 100 mg/ml streptomycin)
for additional 10 min. The liver was carefully removed from the abdominal cavity,
placed in a Petri dish on ice and opened with a forceps. Liver cells were resuspended in
Williams Medium E (supplemented with 10% FCS, 2 mM L-Alanyl-L-Glutamin
(Biochrom, Berlin, Germany), 100 U/ml penicillin, and 100 mg/ml streptomycin)
and put over a 100 mm cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA).
After two rounds of centrifugation (5 min at 50 g and 4uC) and resuspension, cell
viability was determined by trypan blue dye exclusion, and cells were seeded in
serum-free medium on collagen G-coated plates (Biochrom). Adherent hepatocytes
were washed after 2 h with PBS and fresh Williams Medium E (supplemented with
10% FCS, 2 mM L-Alanyl-L-Glutamin, 100 U/ml penicillin, and 100 mg/ml
streptomycin) was added. Stimulation with recombinant cytokines was performed
16 h thereafter.
Generation of human monocyte-derived macrophages. For isolation of peripheral
blood mononuclear cells (PBMC), written informed consent was obtained from
healthy donors, and blood was taken. All experimental protocols were approved by
the ‘Ethik Kommission’ of the University Hospital Goethe-University Frankfurt. The
methods were carried out in accordance with the approved guidelines. Healthy
donors had abstained from taking drugs/medication for 2 weeks before the study.
PBMC were isolated from peripheral blood using Histopaque-1077 (Sigma-Aldrich)
according to the manufacturer’s instructions. The CD141 cell population of PBMC
was isolated by using CD14 antibody-conjugated magnetic microbeads (Miltenyi,
Bergisch-Gladbach, Germany). After isolation, CD141 cell purity was determined by
FACS analysis (FACS Canto, BD Biosciences, Heidelberg, Germany) using a mouse
monoclonal anti-human CD14-phycoerythrin antibody (eBioscience, Frankfurt,
Figure 4 | Application of IL-36Ra exacerbates tissue damage in late
murine APAP-induced liver injury. (a) Mice received either APAP (n 5
16) or APAP/IL-36Ra (n 5 16) and were maintained for 48 h. Thereafter,
serum ALT activity was determined and is depicted as units/liter (means 6
SEM). (b) Mice received either APAP (n 5 8) or APAP/IL-36Ra (n 5 8).
Statistical analysis of necrotic areas in H&E-stained liver sections after
48 h. (ab) Statistical analysis, Student’s t-test. (c) Representative liver
sections (H&E staining) 48 h after the onset of APAP intoxication.
Table 1 | Fold induction of hepatic cytokine mRNA expression after
3h of endotoxemia versus untreated ctrl animals
IL-36c 41.5 6 7.0 p 5 0.0002
CCL20 51.6 6 16.6 p 5 0.0123
TNFa 28.2 6 7.9 p 5 0.0065
IL-1b 30.3 6 9.7 p 5 0.0127
IL-6 67.9 6 19.4 p 5 0.0062
Data are shown as means 6 SEM.
p-values compared to ctrl animals.
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Germany). Enrichment of CD141 cells was .94.9%. Cells were resuspended in
IMDM (supplemented with 2% heat-inactivated human serum (Life Technologies,
Darmstadt, Germany), 100 U/ml penicillin, 100 mg/ml streptomycin, 13
nonessential amino acids, and 50 mM 2-mercaptoethanol) and seeded at a density of
83 105 cells/0.75 ml on 12-well polystyrene plates (Greiner, Frickenhausen,
Germany). For generation of monocyte-derived macrophages, CD141 cells were
cultured in the presence of M-CSF (100 ng/ml) for 7 days. 75% of spent medium was
exchanged for fresh medium and fresh cytokines on days 3 and 5. On day 7
macrophages were stimulated in the aforementioned medium as indicated.
Cultivation of Huh7 cells. The human hepatocellular carcinoma cell line Huh7
(kindly provided by Dr. Kai Breuhahn, Institute of Pathology, University of
Heidelberg, Germany) was maintained in DMEM (with 100 U/ml penicillin, 100 mg/
ml streptomycin, and 10% FCS)60. For experiments, cells were seeded on 6-well
polystyrene plates in the aforementioned culture medium. All incubations were
performed at 37uC and 5% CO2.
Detection of IL-36c by immunoblot analysis. Cell lysates were obtained as
previously described26. Briefly, for detection of proteins, cells were lysed in lysis buffer
(150 mM NaCl, 1 mM CaCl2, 5 mM Tris-Cl (pH 7.4), 1% Triton X-100),
supplemented with protease inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany) and DTT, Na3VO4, PMSF (each 1 mM), and NaF (20 mM). Antibodies:
IL-36c, goat polyclonal antibody (R&D Systems); b-Tubulin, mouse monoclonal
antibody (Santa Cruz Biotechnology).
Analysis of cytokine expression by realtime PCR. After RNA isolation (Tri-Reagent,
Sigma-Aldrich), 1 mg of total RNA was transcribed using hexameric primers and
Moloney virus RT (Life Technologies). Realtime PCR was performed on AbiPrism
7500 Fast Sequence Detector (Life Technologies): one initial step at 95uC for 5 min
was followed by 40 cycles at 95uC for 2 sec and 60uC for 25 sec. Detection of the
dequenched probe, calculation of threshold cycles (Ct values), and data analysis were
performed by the Sequence Detector software. The following probes (Applied
Biosystems) were used (all FAM): mIL-36a, Mm00457645_m1; mIL-36b,
Mm01337546_g1; mIL-36c, Mm00463327_m1; mIL-1Rrp2, Mm00519245_m1;
mCCL20, Mm01268754_m1; mCCL2, Mm00441242_m1; mCXCL2,
Mm00436450_m1; mTNFa, Mm00443285_m1; mIL-1b, Mm00434228_m1; mIL-6,
Mm00446190_m1; hCCL20, Hs01011368_m1; hIL-36c, Hs00219742_m1. mRNA
expression was normalized to GAPDH (mouse: 4352339E; human: 4310884E; both
VIC) and relative changes in the respective mRNA were quantified by the 22ddCt
method.
Analysis of cytokine release by enzyme-linked immunosorbent assay (ELISA).
Murine CCL20 (hepatic protein lysate) was determined by ELISA according to the
manufacturer’s instructions (R&D Systems). For detection of CCL20 in hepatic tissue,
liver specimens were homogenized in lysis buffer (150 mM NaCl, 1 mM CaCl2,
5 mM Tris-Cl (pH 7.4), 1% Triton X-100), supplemented with protease inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany) and DTT, Na3VO4, PMSF (each
1 mM), and NaF (20 mM). To control for background effects, ELISA standard curve
and blank were prepared in corresponding dilutions of lysis buffer.
Statistical analysis. Data were first evaluated with the Kolmogorov-Smirnov test for
parametric distribution. For two groups, raw data were analyzed by an unpaired two-
tailed Student’s t-test. For comparison of three or more groups, raw data were
analyzed by one-way analysis of variance with post hoc Bonferroni correction. Data
are shown as means 6 standard error of the mean (SEM, animal data or cell culture
using primary cells) or as means 6 standard deviation (SD, cell culture data using cell
lines) and are presented as fold induction, pg/500 mg total protein, % (APAP vs.
APAP/IL-36Ra; necrotic area vs. total liver section), units/liter, or as raw data (22ddCt
3 107). Differences were considered statistically significant if the p value was ,0.05
(GraphPad Prism, La Jolla, CA, USA). For analysis by unpaired Student’s t-test
specific p values are indicated whereas in case of analysis by one-way analysis of
variance upper limits of p values are depicted.
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